TrialSpark logo
Home

Our drug development pipeline

Contact us

Drugs currently under development

FOR WEBSITE TrialSpark-Drug-Pipeline 2022-Dec (1)

TrialSpark drugs in the news

PR Newswire

TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio

November 29, 2022
PR Newswire

TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck and forms NewCo

January 10, 2022
BioMed Central

Efficacy and safety of sprifermin injection for knee osteoarthritis treatment: a meta-analysis

April 9, 2021